유전자 패널 시장 규모, 점유율, 동향 분석 리포트 : 제품·서비스별, 방법별, 디자인별, 용도별, 최종 용도별, 지역별, 부문 예측(2024-2030년)

Gene Panel Market Growth & Trends:

The global gene panel market size is expected to reach USD 8.73 billion by 2030, registering to grow at a CAGR of 17.6% from 2024 to 2030 according to a new report by Grand View Research, Inc. A rise in the number of congenital disorders, coupled with an unprecedented increase in the number of cancer cases across the globe, is anticipated to drive the market. Early diagnosis of chromosomal disorders enables timely prognosis and therapeutic steps to be taken so as to retard the symptoms and improve the quality of life.

Furthermore, an increase in hereditary level understanding and a rise in the need for genetic screening, personalized medicine, risk analysis, and prognostics are anticipated to drive the market. A specific group of genes needs to be sequenced and analyzed to understand the genetic predisposition of a disease condition. The panels help in sequencing specific genes that are known to be causative of the disease condition. There are many predesigned panels for particular disease conditions along with options for customization. There also have been consistent research efforts to devise novel gene panels to efficiently diagnose a wide spectrum of genetic disorders.

For instance, INVIEW Liquid Biopsy Onco-profiling is an all-inclusive comprehensive cancer gene panel for examination using liquid biopsy samples like blood. Customizable gene panels are also available that can be customized based on specific requirements. For instance, QIAseq multimodal custom panel is a customizable gene panel that is able to profile variant DNA, RNA fusion, and gene expression patterns from a single sample input.

The COVID-19 pandemic has significantly disrupted the delivery of effective healthcare services, including genetic counseling and genetic testing services. There are efforts across the U.S. to ensure re-igniting genetic testing, at least for pre-implantation screening. However, the ramping up of genetic screening for cancer has also become a part of the mission of cancer societies across the globe.

Moreover, many researchers and clinicians believe that there is a strong necessity for the enforcement of genetic screening procedures to bring down the mortality rate due to genetic disorders, and therefore there will be a rise in the demand for gene panels during the forecast period. For instance, all those born in the U.S. are compulsorily screened using a blood sample for certain genetic, endocrine, metabolic, hearing, and critical congenital heart disorders.

Gene Panel Market Report Highlights:

• By products & services, the test kits segment held the largest share in 2023 due to the utilitarian benefits that a test kit could offer to clinicians, researchers, and the normal population. Ready-to-use kits and self-administrable diagnostic kits are increasingly trending these days
• By technique, the hybridization-based approach is in the growth phase due to the reliability of outcomes, though the technique is expensive and time-consuming. Gene panels are usually designed for the analysis of several genes and the hybridization technique is conducive to this concept of gene panel testing
• By design, predesigned gene panels dominated the market in 2023. This is because predesigned gene panels are preferred over customizable gene panels for diagnostic utility because predesigned panels are backed by research for outcome reliability
• By application, the cancer risk assessment segment is expected to grow lucratively during the forecast period due to a rise in the number of cancer cases and increased recommendations for cancer screening across different countries
• North America dominated the global market in 2023 owing to the increasing demand for genetic screening and early cancer screening, the presence of key players, the rising prevalence of cancer, and rising recommendations for newborn screening

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Gene Panel Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Gene Panel Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Gene Panel Market: Products & Services Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Gene Panel Market: Products & Services Movement Analysis, 2023 & 2030 (USD Million)
• 4.3. Test Kits
  • 4.3.1. Test Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Testing Services
  • 4.4.1. Testing Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Gene Panel Market: Technique Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Gene Panel Market: Technique Movement Analysis, 2023 & 2030 (USD Million)
• 5.3. Amplicon Based Approach
  • 5.3.1. Amplicon Based Approach Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Hybridization Based Approach
  • 5.4.1. Hybridization Based Approach Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Gene Panel Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Gene Panel Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
• 6.3. Academic & Research Institutes
  • 6.3.1. Academic & Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Hospital & Diagnostic Laboratories
  • 6.4.1. Hospital & Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Pharmaceutical & Biotechnology Companies
  • 6.5.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Gene Panel Market: Application Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Gene Panel Market: Application Movement Analysis, 2023 & 2030 (USD Million)
• 7.3. Cancer Risk Assessment
  • 7.3.1. Cancer Risk Assessment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Diagnosis of Congenital Diseases
  • 7.4.1. Diagnosis of Congenital Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Pharmacogenetics
  • 7.5.1. Pharmacogenetics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Other Applications.
  • 7.6.1. Other Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Gene Panel Market: Regional Estimates & Trend Analysis

• 8.1. Gene Panel Market Share, By Region, 2023 & 2030 (USD Million)
• 8.2. North America
  • 8.2.1. North America Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Canada Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Mexico Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. UK Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Germany Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. France Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.4. Asia Pacifics
  • 8.4.1. Asia Pacific Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. China
    • 8.4.2.1. China Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Japan
    • 8.4.3.1. Japan Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. India Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.5. South Korea
    • 8.4.5.1. South Korea Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.6. Australia
    • 8.4.6.1. Australia Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Brazil Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Middle East and Africa
  • 8.6.1. Middle East and Africa Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Saudi Arabia
    • 8.6.2.1. Saudi Arabia Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. UAE
    • 8.6.3.1. UAE Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. South Africa
    • 8.6.4.1. South Africa Gene Panel Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis by Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Heat Map Analysis
• 9.4. Company Profiles
  • 9.4.1. Agilent Technologies
    • 9.4.1.1. Participant's Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Recent Developments/ Strategic Initiatives
  • 9.4.2. Illumina Inc.
    • 9.4.2.1. Participant's Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Recent Developments/ Strategic Initiatives
  • 9.4.3. Qiagen Inc.
    • 9.4.3.1. Participant's Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Recent Developments/ Strategic Initiatives
  • 9.4.4. Eurofins Genomics
    • 9.4.4.1. Participant's Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Recent Developments/ Strategic Initiatives
  • 9.4.5. Thermo Fisher Scientific, Inc.
    • 9.4.5.1. Participant's Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Recent Developments/ Strategic Initiatives
  • 9.4.6. Foundation Medicine, Inc.
    • 9.4.6.1. Participant's Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Recent Developments/ Strategic Initiatives
  • 9.4.7. Guardant Health, Inc.
    • 9.4.7.1. Participant's Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Recent Developments/ Strategic Initiatives
  • 9.4.8. Cepheid
    • 9.4.8.1. Participant's Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Recent Developments/ Strategic Initiatives
  • 9.4.9. Bio-Rad Laboratories, Inc.
    • 9.4.9.1. Participant's Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Recent Developments/ Strategic Initiatives
  • 9.4.10. Personalis
    • 9.4.10.1. Participant's Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Recent Developments/ Strategic Initiatives